denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.Hematology Disease Topics & Pathways:
Research, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Diseases, Treatment Considerations, Biological therapies, Lymphoid Malignancies
Description:
The prolonged survival for most patients with newly diagnosed follicular lymphoma in 2024 is a triumph of the introduction of rituximab a quarter of a century ago. Our improved understanding of follicular lymphoma biology, the heterogeneity of both disease and patients, and new therapeutic options help us in “choosing wisely” the sequencing of treatment for a given patient. We can now be confident of a median 10 years between first and second treatments along with an age-matched survival for patients in sustained remission after immunochemotherapy. In this session, we map the remaining challenges of identifying the minority of patients with early progression and a poor prognosis, as well as the sequencing of the highly promising T-cell immunotherapies for patients with early or multiply-relapsed disease.
In this talk, Dr. Trotman will provide the survival data to equip clinicians in framing optimistic initial conversations with most patients at diagnosis of advanced stage FL. She outlines the expectations of longevity and a “functional cure” for many. She will address considerations of both patient and FL heterogeneity when discussing initial therapy of high tumor burden disease. She provides the data to assist patients who have achieved complete metabolic remission with prognostication and life planning after initial immunochemotherapy.
In this talk, Dr. Casulo will review the origins of POD24 and its impact on survival outcomes in follicular lymphoma. She will review currently available biomarkers and risk calculators for POD24, providing updates on the pathobiology influencing follicular lymphoma prognosis and implicated in POD24. This talk will also explore the impact of histologic transformation on survival in POD24 and outline future directions for management of POD24 in the current era.
Dr. Bartlett will discuss the activity and safety of anti-CD3xCD20 bispecific antibody T-cell engagers and anti-CD19 autologous chimeric antigen receptor T-cells for relapsed or refractory follicular lymphoma. She will review the pivotal clinical trial data, highlighting depth and durations of responses as well as toxicities including cytokine release syndrome, infections, and neurologic events. She will describe a framework for sequencing these classes of agents, additionally taking into account patient factors and logistical considerations.
In this talk, Dr. Trotman will provide the survival data to equip clinicians in framing optimistic initial conversations with most patients at diagnosis of advanced stage FL. She outlines the expectations of longevity and a “functional cure” for many. She will address considerations of both patient and FL heterogeneity when discussing initial therapy of high tumor burden disease. She provides the data to assist patients who have achieved complete metabolic remission with prognostication and life planning after initial immunochemotherapy.
In this talk, Dr. Casulo will review the origins of POD24 and its impact on survival outcomes in follicular lymphoma. She will review currently available biomarkers and risk calculators for POD24, providing updates on the pathobiology influencing follicular lymphoma prognosis and implicated in POD24. This talk will also explore the impact of histologic transformation on survival in POD24 and outline future directions for management of POD24 in the current era.
Dr. Bartlett will discuss the activity and safety of anti-CD3xCD20 bispecific antibody T-cell engagers and anti-CD19 autologous chimeric antigen receptor T-cells for relapsed or refractory follicular lymphoma. She will review the pivotal clinical trial data, highlighting depth and durations of responses as well as toxicities including cytokine release syndrome, infections, and neurologic events. She will describe a framework for sequencing these classes of agents, additionally taking into account patient factors and logistical considerations.